Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GEMOX vs XELOX in advanced biliary tract carcinoma
NCT01470443Phase 3Unknown
- Sponsor
- Samsung Medical Center
- Start
- Dec 2011
- Primary completion
- Dec 2016
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of capecitabine in biliary tract carcinoma (BTC), sponsored by Samsung Medical Center. Status: unknown.
02
Drugs
capecitabine
03
Conditions
biliary tract carcinoma (BTC)
Beyond the preview
Go deeper on NCT01470443.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01470443.